Insmed | INSM - Ebitda

Aktienkurs
143.83
Täglich Wechseln
7.83 5.76%
Monatlich
-9.32%
Jährlich
81.19%
Q1 Prognose
131.92




Ebitda Veränderung Datum
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Cytokinetics USD -277.18M 169.36M 2025-09
DBV Technologies USD -33.48M 5.55M 2025-09
Gilead Sciences USD 4.03B 628M 2025-09
Heron Therapeutics USD -3.88M 5.63M 2024-09
Insmed USD -314.19M 31.48M 2025-12
Novartis USD 5.84B 235M 2025-09
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09